Email: cspc@cspc.cn
Media
News Center
Nov. 23
2023
VOLUNTARY ANNOUNCEMENT - KN026 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Nov. 04
VOLUNTARY ANNOUNCEMENT - MONOCLONAL ANTIBODY DRUG (SYS6011) OBTAINS CLINICAL TRIAL APPROVAL
Nov. 02
VOLUNTARY ANNOUNCEMENT - SECUKINUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Oct. 31
CSPC's DP303c Research Findings Presented at ESMO
150 Party Organization Secretaries Visit CSPC
VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
